Atara Biotherapeutics (DB:AT20) - Hisse Senedi Fiyatı, Haberler ve Analizler

AT20 Stoklara Genel Bakış

Engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.

Şirket hakkında

AT20 temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 82% daha düşük bir oranda işlem görüyor

Gelirin yılda 17.81% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 5% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

Negatif hissedar öz sermayesi

Anlamlı bir piyasa değeri yok ( €48M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Atara Biotherapeutics, Inc. Rakipler

Heidelberg Pharma

XTRA:HPHA

€118.4m

Medigene

XTRA:MDG1

€24.1m

2invest

XTRA:2INV

€59.8m

co.don

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Atara Biotherapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$9.25
52 Haftanın En Yüksek Seviyesi	US$41.60
52 Haftanın En Düşük Seviyesi	US$4.49
Beta	0.50
11 Aylık Değişim	0%
3 Aylık Değişim	-26.00%
1 Yıllık Değişim	-74.19%
33 Yıllık Değişim	-97.25%
5 Yıllık Değişim	-97.31%
Halka arzdan bu yana değişim	-96.78%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	AT20	DE Biotechs	DE Pazar
7D	0%	0.5%	-1.4%
1Y	-74.2%	-16.2%	11.8%

Getiri vs. Endüstri: AT20 geçen yıl % -16.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: AT20 geçen yıl % 11.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AT20's price volatile compared to industry and market?
AT20 volatility
AT20 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: AT20 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AT20 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	165	Pascal Touchon	www.atarabio.com

Atara Biotherapeutics, Inc. Temel Bilgiler Özeti

Atara Biotherapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AT20 temel i̇stati̇sti̇kler
Piyasa değeri	€43.13m
Kazançlar(TTM)	-€163.43m
Gelir(TTM)	€56.32m

0.8x

P/S Oranı

-0.3x

F/K Oranı

AT20 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AT20 gelir tablosu (TTM)
Gelir	US$62.39m
Gelir Maliyeti	US$188.34m
Brüt Kâr	-US$125.96m
Diğer Giderler	US$55.09m
Kazançlar	-US$181.05m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-36.84
Brüt Marj	-201.90%
Net Kâr Marjı	-290.20%
Borç/Özkaynak Oranı	0%

AT20 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AT20 Stoklara Genel Bakış

Ödüller

Risk Analizi

Atara Biotherapeutics, Inc. Rakipler

XTRA:HPHA

€118.4m

XTRA:MDG1

€24.1m

XTRA:2INV

€59.8m

XTRA:CNW

€6.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

Recent updates

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought €95k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Third quarter 2022 earnings released: US$0.82 loss per share (vs US$0.91 loss in 3Q 2021)

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought €413k worth of stock